10-Q · May 12, 2026
Coya Therapeutics reported Q1 2026 results showing a slight improvement in net loss year-over-year as they managed expenses better. However, revenue remained stagnant at $0.3 million with further expected cash burn due…
Earnings analysis · 10-Q
COYA earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt is limited to controls, legal proceedings, risk factors, and exhibits; it does not include the income statement, balance sheet, cash-flow statement, segment data, or MD&A needed to assess…
Read full summary
The provided 10-Q excerpt is limited to controls, legal proceedings, risk factors, and exhibits; it does not include the income statement, balance sheet, cash-flow statement, segment data, or MD&A needed to assess operating trends. Disclosure controls were deemed effective as of June 30, 2026, and management reported no material changes in internal control over financial reporting. No material risk-factor changes were disclosed versus the December 31, 2025 10-K or the March 31, 2026 10-Q, and no quantitative guidance was provided in the available text.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management evaluated disclosure controls as of June 30, 2026 and concluded they were effective at the reasonable-assurance level.
-
No material control changes
The filing states there was no change during the period in internal control over financial reporting that materially affected, or was reasonably likely to materially affect, those controls.
-
No legal proceedings reported
The company reported no legal proceedings in Item 1 of Part II.
What to watch
-
Existing risks remain unchanged
The filing states there were no material changes to the risk factors disclosed in the December 31, 2025 Form 10-K filed March 16, 2026, or the March 31, 2026 Form 10-Q filed May 12, 2026. Existing risks therefore remain applicable, but no new or changed risk was identified in this filing.
-
Inherent control limitations
The company states that internal controls cannot prevent or detect all misstatements because of their inherent limitations, and that projections of control effectiveness into future periods may be affected by changing conditions or deteriorating compliance.
-
Potential equity financing exposure
The filing identifies a Sales Agreement with Leerink Partners LLC dated May 12, 2026 as Exhibit 10.1. The provided excerpt does not disclose proceeds, capacity, or actual sales under the agreement, so potential equity-financing dilution cannot be quantified here.
Management's outlook
The provided filing excerpt contains no quantitative revenue, EPS, cash-flow, operating outlook, or other numeric guidance. Outlook is not provided in the available text.
Earlier filings 4
10-K · March 16, 2026
Coya Therapeutics is a clinical-stage biotech focused on Treg-enhancing therapies with COYA 302 as its lead asset; the FDA accepted its IND for COYA 302 in August 2025 and patient dosing began in December 2025. The…
10-Q · November 12, 2025
Coya reported Q3 2025 collaboration revenue of $3,564,254 and a reduced operating loss of $2,432,897 (operating margin -68.3%) versus an operating loss of $4,450,289 in Q3 2024. GAAP net loss per share improved to…
10-Q · August 12, 2024
Coya reported Q2 collaboration revenue of $3,425,271 and a net loss per share of $(0.19), improving from $(0.31) in Q2 2023. The company generated positive financing activity (net proceeds $6.39M YTD) and ended the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.